A DNA-binding Molecule Targeting the Adaptive Hypoxic Response in Multiple Myeloma Has Potent Antitumor Activity

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Molecular Cancer Research

• Publication date

  2016-01-22

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/1541-7786.MCR-15-0361PMID 26801054PMCID PMC4794370
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Metabolic signature identifies novel targets for drug resistance in multiple myeloma.

  2015influential reference
• Direct measurement of local oxygen concentration in the bone marrow of live animals

  2014cited by this paper
• A C-14 labeled Py-Im polyamide localizes to a subcutaneous prostate cancer tumor.

  2014cited by this paper
• Results from AMBER, a randomized phase 2 study of bevacizumab and bortezomib versus bortezomib in relapsed or refractory multiple myeloma

  2013cited by this paper
• Synergistic Induction of Apoptosis in Multiple Myeloma Cells by Bortezomib and Hypoxia-Activated Prodrug TH-302, In Vivo and In Vitro

  2013cited by this paper
• Mammalian Target of Rapamycin Inhibitors Induce Tumor Cell Apoptosis In Vivo Primarily by Inhibiting VEGF Expression and Angiogenesis

  2013influential reference
• Anti-VEGF/VEGFR therapy for cancer: reassessing the target.

  2012cited by this paper
• The updated biology of hypoxia‐inducible factor

  2012cited by this paper
• Gene expression changes in a tumor xenograft by a pyrrole-imidazole polyamide

  2012cited by this paper
• The emerging role of hypoxia, HIF-1 and HIF-2 in multiple myeloma

  2011cited by this paper
• mechanisms of disease Oxygen Sensing , Homeostasis , and Disease

  2011cited by this paper
• Oxygen sensing, homeostasis, and disease.

  2011cited by this paper
• Bone marrow angiogenesis and progression in multiple myeloma.

  2011cited by this paper
• Treatment Options for Relapsed and Refractory Multiple Myeloma

  2011cited by this paper
• Hypoxia and activated VEGF/receptor pathway in multiple myeloma.

  2010cited by this paper
• The prolyl‐hydroxylase EGLN3 and not EGLN1 is inactivated by methylation in plasma cell neoplasia

  2010cited by this paper
• A therapeutic role for targeting c-Myc/Hif-1-dependent signaling pathways.

  2010cited by this paper
• Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug.

  2010cited by this paper
• Hypoxia-inducible factor-2 is a novel regulator of aberrant CXCL12 expression in multiple myeloma plasma cells

  2010cited by this paper
• A SNP microarray and FISH‐based procedure to detect allelic imbalances in multiple myeloma: An integrated genomics approach reveals a wide gene dosage effect

  2009cited by this paper
• Role of the phosphatidylinositol-3-kinase and extracellular regulated kinase pathways in the induction of hypoxia-inducible factor (HIF)-1 activity and the HIF-1 target vascular endothelial growth factor in ovarian granulosa cells in response to follicle-stimulating hormone.

  2009cited by this paper
• Regulation of D-cyclin translation inhibition in myeloma cells treated with mammalian target of rapamycin inhibitors: rationale for combined treatment with extracellular signal–regulated kinase inhibitors and rapamycin

  2009cited by this paper
• Inhibition of hypoxia-inducible factor-1 function enhances the sensitivity of multiple myeloma cells to melphalan

  2009cited by this paper
• Bone marrow microenvironment and the identification of new targets for myeloma therapy

  2009cited by this paper
• Improved survival in multiple myeloma and the impact of novel therapies.

  2008cited by this paper
• Abnormal Sympathoadrenal Development and Systemic Hypotension in PHD3−/− Mice

  2008cited by this paper
• Role and regulation of prolyl hydroxylase domain proteins

  2008cited by this paper
• A hypoxia-controlled cap-dependent to cap-independent translation switch in breast cancer.

  2007cited by this paper
• AKT activity regulates the ability of mTOR inhibitors to prevent angiogenesis and VEGF expression in multiple myeloma cells

  2007cited by this paper
• Modulating hypoxia-inducible transcription by disrupting the HIF-1-DNA interface.

  2007cited by this paper
• Hypoxia signalling in cancer and approaches to enforce tumour regression

  2006cited by this paper
• Regulating cellular oxygen sensing by hydroxylation.

  2006cited by this paper
• Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis.

  2006cited by this paper
• Contrasting Properties of Hypoxia-Inducible Factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-Associated Renal Cell Carcinoma

  2005cited by this paper
• Role of the hypoxic bone marrow microenvironment in 5T2MM murine myeloma tumor progression.

  2005cited by this paper
• ONCOMINE: a cancer microarray database and integrated data-mining platform.

  2004cited by this paper
• In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model.

  2004influential reference
• Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma

  2004cited by this paper
• Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex.

  2004influential reference
• Inhibition of vascular endothelial growth factor with a sequence-specific hypoxia response element antagonist.

  2004cited by this paper
• Establishment of a new model of human multiple myeloma using NOD/SCID/gammac(null) (NOG) mice.

  2004cited by this paper
• HIF prolyl‐hydroxylase 2 is the key oxygen sensor setting low steady‐state levels of HIF‐1α in normoxia

  2003cited by this paper
• Mutations to CCI-779 PTEN Enhanced Sensitivity of Multiple Myeloma Cells Containing Updated Version

  2002cited by this paper
• Molecular basis of the VHL hereditary cancer syndrome

  2002cited by this paper
• Solid-phase synthesis of DNA binding polyamides on oxime resin.

  2002cited by this paper
• Hypoxia-inducible factor-1alpha mRNA contains an internal ribosome entry site that allows efficient translation during normoxia and hypoxia.

  2002cited by this paper
• Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model.

  2002cited by this paper
• Biological consequences of tumor hypoxia.

  2001cited by this paper
• Novel therapies targeting the myeloma cell and its bone marrow microenvironment.

  2001cited by this paper
• Prognostic value of bone marrow angiogenesis in multiple myeloma.

  2000cited by this paper
• Bone marrow of patients with active multiple myeloma: Angiogenesis and plasma cell adhesion molecules LFA‐1, VLA‐4, LAM‐1, and CD44

  1995cited by this paper
• Bone marrow angiogenesis and progression in multiple myeloma

  1994cited by this paper
• Hypoxia-inducible Factor-1 (cid:1) mRNA Contains an Internal Ribosome Entry Site That Allows Efficient Translation during Normoxia and Hypoxia

  year unknowncited by this paper

• mTOR activity and metabolic reprogramming of CD8+ T cells is impaired under hypoxia and within the multiple myeloma bone marrow

  2025cites this paper
• Chemical Control of Genes: Synthetic Genome Readers and Gene Regulators.

  2025cites this paper
• Acidification of intracellular pH in MM tumor cells overcomes resistance to hypoxia-mediated apoptosis in vitro and in vivo

  2023cites this paper
• A Comprehensive Description of Hypoxia-inducible Factor 2α Inhibitors as Anticancer Agents: A mini-review.

  2022cites this paper
• Can Targeting Hypoxia-Mediated Acidification of the Bone Marrow Microenvironment Kill Myeloma Tumor Cells?

  2021cites this paper
• Synthetic DNA Binding Assembly: Architecture, Application and Perspectives

  2020cites this paper
• Therapeutic gene regulation using pyrrole-imidazole polyamides.

  2019cites this paper
• Pharmacologic Targeting of Hypoxia-Inducible Factors.

  2019cites this paper
• Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice.

  2019cites this paper
• Modulation of nuclear receptor function: Targeting the protein-DNA interface.

  2019cites this paper
• Introduction: Sequence-Specific DNA Binding Pyrrole–Imidazole Polyamides and Their Applications

  2019cites this paper
• A Novel Therapeutic Induces DEPTOR Degradation in Multiple Myeloma Cells with Resulting Tumor Cytotoxicity

  2019cites this paper
• Structure-Function Relationships of the Nucleocapsid in Vesicular Stomatitis Virus

  2018cites this paper
• A Polyamide Inhibits Replication of Vesicular Stomatitis Virus by Targeting RNA in the Nucleocapsid

  2018cites this paper
• Targeting Transcription Factors for Cancer Treatment

  2018cites this paper
• Targeting the hypoxia pathway in malignant plasma cells by using 17-allylamino-17-demethoxygeldanamycin.

  2018cites this paper
• Sequence-specific DNA binding Pyrrole-imidazole polyamides and their applications.

  2018cites this paper
• Restoration of the prolyl-hydroxylase domain protein-3 oxygen-sensing mechanism is responsible for regulation of HIF2α expression and induction of sensitivity of myeloma cells to hypoxia-mediated apoptosis

  2017cites this paper
• A computational protocol for the discovery of lead molecules targeting DNA unique to pathogens.

  2017cites this paper